Article ID Journal Published Year Pages File Type
2927261 IJC Metabolic & Endocrine 2014 8 Pages PDF
Abstract

•1251 subjects undergoing coronary and peripheral angiographic procedures enrolled•Blood samples were obtained immediately before and after the procedure.•Cardiac and renal biomarkers will be examined for identifying periprocedural events.•Follow-up of up to six years has been completed for short and long-term events.•Data from the first 491 patients have been obtained (190 patients with 1-year events).

BackgroundThe ability to identify peri-procedural complications or predict short and long-term adverse outcomes in patients undergoing cardiac or peripheral angiography is imperfect.MethodsIn a prospective single-center trial, 1251 subjects undergoing coronary and peripheral angiographic procedures ± intervention between 2008 and 2011 were enrolled to evaluate the use of cardiac and renal biomarkers for identifying peri-procedural events and predicting short and long-term events. Blood samples were taken immediately before and after the procedure. Clinical and angiographic characteristics were recorded. The primary end point is peri-procedural combined end point of major adverse cardiovascular events (MACE: death, myocardial infarction (MI), heart failure (HF), stroke, transient ischemic attack, peripheral arterial complication and cardiac arrhythmia). Secondary end points are assessed at peri-procedural, 30-day and 1-year, and include MACE and individual end points as well as renal complications including acute kidney injury (AKI) and worsening of chronic kidney disease. Extended follow-up of up to 6 years has also been completed.ResultsData from the first 491 patients have been obtained with 190 patients experiencing at least one MACE at 1-year follow-up with the following number of patients experiencing at least one specified event; 80 deaths, 39 MI, 73 HF, 21 neurological events, 37 peripheral arterial complications and 59 arrhythmias; additionally there were 55 patients with AKI.ConclusionsThe CASABLANCA study will examine the role of novel biomarkers and metabolomics for predicting a wide range of cardiovascular, neurologic, and renal complications in patients undergoing angiography. Full results are expected in the latter half of 2014 (ClinicalTrials.Gov # NCT00842868).

Related Topics
Health Sciences Medicine and Dentistry Cardiology and Cardiovascular Medicine
Authors
, , , , , , , , , , , , ,